Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer

Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT06765616 by Feng Tian, with a registry enrolment figure of 31 participants, started 2024-01-01 and due to reach its primary completion in 2025-07-01. Interventions recorded: Adebrelimab Injection combined with radiotherapy and chemotherapy. Conditions listed: Rectal Cancer; Advanced Stage Colorectal Cancer; Radiotherapy. Primary outcome: Pathological complete remission rate (pCR). Colorectal eligibility wording from the registry: "Patients diagnosed with rectal adenocarcinoma through primary lesion biopsy and histopathological examination;". Sites: China. No results are recorded here; the registry entry is the source.